Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA-Directed DNA Polymerase | 10 | 2019 | 89 | 1.740 |
Why?
|
| DNA | 7 | 2021 | 549 | 1.190 |
Why?
|
| DNA Helicases | 3 | 2021 | 150 | 0.890 |
Why?
|
| G-Quadruplexes | 4 | 2020 | 77 | 0.860 |
Why?
|
| DNA Replication | 4 | 2020 | 160 | 0.780 |
Why?
|
| Enzyme Inhibitors | 3 | 2020 | 372 | 0.760 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2020 | 181 | 0.610 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 474 | 0.570 |
Why?
|
| DNA Primase | 2 | 2020 | 8 | 0.500 |
Why?
|
| Cisplatin | 1 | 2018 | 285 | 0.500 |
Why?
|
| DNA Damage | 6 | 2020 | 307 | 0.490 |
Why?
|
| Biocatalysis | 1 | 2014 | 15 | 0.460 |
Why?
|
| Manganese | 1 | 2014 | 23 | 0.450 |
Why?
|
| Magnesium | 1 | 2014 | 32 | 0.450 |
Why?
|
| Models, Molecular | 2 | 2014 | 352 | 0.430 |
Why?
|
| Up-Regulation | 1 | 2014 | 462 | 0.400 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1221 | 0.390 |
Why?
|
| Neoplasms | 2 | 2018 | 1308 | 0.340 |
Why?
|
| Indoles | 3 | 2019 | 277 | 0.330 |
Why?
|
| Nuclear Proteins | 2 | 2020 | 247 | 0.240 |
Why?
|
| Deoxyguanosine | 2 | 2014 | 27 | 0.230 |
Why?
|
| RecQ Helicases | 2 | 2014 | 22 | 0.210 |
Why?
|
| Kinetics | 5 | 2016 | 622 | 0.200 |
Why?
|
| Signal Transduction | 2 | 2021 | 1714 | 0.200 |
Why?
|
| Bacteriophage T4 | 1 | 2021 | 29 | 0.180 |
Why?
|
| Benzopyrans | 1 | 2020 | 11 | 0.170 |
Why?
|
| DNA Polymerase beta | 1 | 2020 | 13 | 0.170 |
Why?
|
| Viral Proteins | 1 | 2021 | 164 | 0.170 |
Why?
|
| Homologous Recombination | 1 | 2020 | 41 | 0.160 |
Why?
|
| Molecular Docking Simulation | 2 | 2018 | 88 | 0.160 |
Why?
|
| Substrate Specificity | 3 | 2015 | 196 | 0.160 |
Why?
|
| HEK293 Cells | 1 | 2020 | 232 | 0.160 |
Why?
|
| Humans | 14 | 2021 | 52593 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2020 | 320 | 0.140 |
Why?
|
| Thiobarbiturates | 1 | 2018 | 22 | 0.140 |
Why?
|
| DNA Primers | 2 | 2015 | 206 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 1436 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 67 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 426 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2018 | 200 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 134 | 0.130 |
Why?
|
| Exodeoxyribonucleases | 2 | 2014 | 21 | 0.130 |
Why?
|
| DNA Repair | 1 | 2017 | 196 | 0.130 |
Why?
|
| DNA Polymerase II | 1 | 2015 | 9 | 0.120 |
Why?
|
| Templates, Genetic | 1 | 2014 | 13 | 0.110 |
Why?
|
| DNA Adducts | 1 | 2014 | 79 | 0.110 |
Why?
|
| Nucleotidyltransferases | 1 | 2013 | 15 | 0.110 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2013 | 4 | 0.100 |
Why?
|
| Leukotrienes | 1 | 2013 | 9 | 0.100 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2013 | 15 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 496 | 0.100 |
Why?
|
| Deoxyribonucleotides | 1 | 2012 | 4 | 0.100 |
Why?
|
| Sulfolobus solfataricus | 1 | 2012 | 22 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 2012 | 85 | 0.100 |
Why?
|
| Nucleotides | 1 | 2012 | 24 | 0.100 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 209 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2020 | 74 | 0.080 |
Why?
|
| Animals | 1 | 2017 | 13507 | 0.050 |
Why?
|
| Streptavidin | 1 | 2021 | 17 | 0.050 |
Why?
|
| DNA, Single-Stranded | 1 | 2021 | 88 | 0.040 |
Why?
|
| Phenol | 1 | 2020 | 7 | 0.040 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 21 | 0.040 |
Why?
|
| Chromosome Fragile Sites | 1 | 2020 | 2 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2021 | 154 | 0.040 |
Why?
|
| DNA Polymerase I | 1 | 2020 | 7 | 0.040 |
Why?
|
| S Phase | 1 | 2020 | 19 | 0.040 |
Why?
|
| Eukaryota | 1 | 2020 | 10 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2020 | 13 | 0.040 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 17 | 0.040 |
Why?
|
| Vitamin E | 1 | 2020 | 77 | 0.040 |
Why?
|
| Drug Design | 1 | 2020 | 121 | 0.040 |
Why?
|
| Temperature | 1 | 2020 | 165 | 0.040 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2020 | 71 | 0.040 |
Why?
|
| Genome, Human | 1 | 2020 | 121 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 405 | 0.040 |
Why?
|
| Alkylation | 1 | 2019 | 10 | 0.040 |
Why?
|
| Chromatin | 1 | 2020 | 141 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 170 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 327 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2020 | 530 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 361 | 0.040 |
Why?
|
| Fluorescence Polarization | 1 | 2016 | 17 | 0.030 |
Why?
|
| Base Pair Mismatch | 1 | 2015 | 21 | 0.030 |
Why?
|
| Deoxycytidine Monophosphate | 1 | 2013 | 5 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 252 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2014 | 261 | 0.030 |
Why?
|
| Guanine | 1 | 2013 | 40 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 673 | 0.030 |
Why?
|
| Carbohydrate Conformation | 1 | 2012 | 4 | 0.030 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2012 | 4 | 0.030 |
Why?
|
| DNA, Archaeal | 1 | 2012 | 10 | 0.020 |
Why?
|
| Catalysis | 1 | 2012 | 89 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2012 | 61 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 156 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 377 | 0.020 |
Why?
|